Dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved well-controlled disease statusConfirmatory data to support US regulatory resubmission by year-end; if ...
On top of this, a stock split generally shows a company is confident about the future, with the idea that the stock could ...
Barclays analyst Carter Gould assigned a Buy rating to Regeneron (REGN – Research Report) today and set a price target of $1,080.00. The company’s shares closed last Friday at $933.02. According to ...
CENTRAL TRUST Co lessened its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 18.7% in ...
Eli Lilly's Ebglyss improves skin and itch symptoms in eczema patients, including Dupixent-treated cases, with positive Phase ...
The growth of the birch allergy treatment market can be attributed to the increasing prevalence of birch allergies, ...
Key drugs from Johnson & Johnson and Eli Lilly stand to bolster their respective cases in competitive dermatology markets ...
The British pharma is making what it calls its largest U.S. manufacturing investment. Elsewhere, AbbVie expanded a ...
In the wake of the elimination diets, 38% of the parents reported no improvement in their child’s AD, 35% reported a 25% ...
It was generously donated by Regeneron as one of at least 200 community projects that the company has done just this week. The playground was finished Wednesday. The Schuyler Inn is a former motel ...
As we previously reported, on September 24, 2024, the District Court for the Northern District of West Virginia denied Regeneron’s motion seeking ...
Sunir Garg, MD, shares insights on new data on aflibercept 8 mg, faricimab, and the impact of social determinants of health, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback